Won 2018 Master’s Award: Recognized by Leadership for being a Top Performer. 1/14-9/17: Primary Merck Oncology Point-of-Contact for Key Academic Medical Centers (AMC) & large Integrated Delivery Networks (IDN) in S. California.Primary Product Responsibility: Keytruda (PD-1 inhibitor) indicated in Non-Small Cell Lung Cancer (NSCLC), Melanoma, Head & Neck Squamous Cell Cancer, Urothelial Carcinoma, Microsatellite Instability-High Carcinoma, Classical Hodgkin Lymphoma & many additional indications.Build & establish customer relationships within AMCs & IDNs with Executive Decision Makers, Key Opinion Leaders & Scientific Leaders and establish above-the-brand collaborative initiatives.Responsible for development of account launch plans for each of Keytruda's FDA indications & leading key account team meetings with district managers, sales representatives, reimbursement associates, nurse educators & diagnostic specialists to ensure team alignment on responsibilities, effective coordination of efforts & execution of plans.Work closely with Health Science Oncology Medical Affairs Directors.Proficient in account segmentation, customer models & account drivers to successfully launch products & drive sales results.10/17: New partnership with AstraZeneca. Transitioned into Merck/AZ KAM role. Expanded into Women’s Cancers with Lynparza & Keytruda MSI-H. Led Women’s Cancers Account teams with both Merck & AZ peers & counterparts.Primary Product Responsibility for Lynparza: PARP inhibitor (targeted oral therapy) for appropriate Ovarian Cancer & Breast Cancer patients. Develop ongoing strategic account plans for S. California AMCs & Arizona Oncology. Plans include account goals, tactics & agreed-upon execution dates by team.Speaker Liaison for Merck products. Identify, train & certify speakers on all promotional presentations.Received several "Awards of Excellence" from Oncology Leadership for outstanding leadership skills & collaborative efforts.

Account Executive: Responsible for contract negotiations, contract development and execution. Clarified terms and conditions and coordinated pull-through activities with McKesson Specialty Health (MSH), USO and OnMark GPOs.Key Customers included: C Suite Execs, practice administrators and key influencers at targeted, practices and clinics with Key Opinion Leaders across the U.S.Coordinated efforts between Lilly cross-functional teams (Brand, Payer Services, Marketing, P2P, Legal and Compliance). Develop national pull-through initiatives to achieve Alimta growth goals. Quarterly business reviews with MSH, USO and OnMark to evaluate business objectives, performance and pull-through strategies.Identified and provided support for targeted account six sigma projects.Pull Through - Collaborated with Directors, DSMs, Reimbursement Specialists and sales specialists to align strategies and deliver appropriate resources and initiatives to address customer’s needs and drive product utilization.Oncology Executive Sales: Top 6% in nation - Alimta Sales @ 108%Management and Leadership Development Program for managerial career path.Partnered with key accounts in geography to build awareness around cancer treatment by providing non-branded resources such as: Lilly Oncology on Canvas Art Exhibit; Dealing with Grief and Loss; Survivorship awareness Mentored numerous oncology sales specialistsCreated national job aid/reference guide for oncology field-based representativesTrained Canadian affiliate on sales modelExtensive Neuroscience Experience Zyprexa Brand Message Development TeamImplemented Wellness initiative as a system wide program for the County Mental Health Clinics at Los Angeles County Department of Mental Health

Increased performance quotient for territory from 25.6% (hire date) to 95.22%Top 9% in nation for Aciphex growthTop 10% in nation for Sporanox growthWon Duragesic “Raise the Volume” contest and attained gold status by increasing volume 54.95% in 4th quarter vs 3rd quarter, 2000.

Maintained #1 market share in District for Paxil, top 15% of nation, Dec 1999Attained #1 market share in District for Augmentin, top 18% of nation, Dec 1999Successfully launched Requip for Parkinson’s disease and consistently remained among top 3 in district.